Dr Danny Rischin

Honorary Associate
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone 03 9656 1804

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Finnigan, R., Hruby, G., Wratten, C., Keller, J., Tripcony, L., Dickie, G., Rischin, D., Poulsen, M. (2013). The Impact of Preradiation Residual Disease Volume on Time to Locoregional Failure in Cutaneous Merkel Cell Carcinoma-A TROG Substudy. International Journal of Radiation Oncology, Biology, Physics, 86(1), 91-95. [More Information]
  • Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 8(3), 248-254. [More Information]
  • Collins, I., Roberts-Thomson, R., Faulkner, D., Rischin, D., Friedlander, M., Mileshkin, L. (2011). Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls. International Journal Of Gynecological Cancer, 21(7), 1213-1218. [More Information]
  • Anglesio, M., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P., House, C., deFazio, A., et al (2011). IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 17(8), 2538-2548. [More Information]
  • Reck, M., van Zandwijk, N., Gridelli, C., Baliko, Z., Rischin, D., Allan, S., Krzakowski, M., Heigener, D. (2010). Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. Journal of Thoracic Oncology, 5(10), 1616-1622. [More Information]
  • Tinker, A., Gebski, V., Fitzharris, B., Buck, M., Stuart-Harris, R., Beale, P., Goldrick, A., Rischin, D. (2007). Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01. Gynecologic Oncology, 104(3), 647-653. [More Information]
  • Rischin, D., Peters, L., Fisher, R., Macann, A., Denham, J., Poulsen, M., Jackson, M., Kenny, L., Penniment, M., Corry, J., et al (2005). Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). Journal of Clinical Oncology, 23(1), 79-87. [More Information]
  • Rischin, D., Phillips, K., Friedlander, M., Harnett, P., Quinn, M., Richardson, G., Martin, A. (2004). A Phase II Trial Of Capecitabine In Heavily Pre-Treated Platinum-Resistant Ovarian Cancer. Gynecologic Oncology, 93(2), 417-421.
  • Millward, M., Boyer, M., Lehnert, M., Clarke, S., Rischin, D., Goh, B., Wong, J., McNeil, E., Bishop, J. (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Annals of Oncology, 14(3), 449-454.
  • Gore, M., Atkinson, R., Thomas, H., Cure, H., Rischin, D., Beale, P., Bougnoux, P., Dirix, L., Smit, W. (2002). A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. European Journal of Cancer, 38(18), 2416-2420.
  • Rischin, D., Ackland, S., Smith, J., Garg, M., Clarke, S., Millward, M., Toner, G., Zalcberg, J. (2002). Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies. Annals of Oncology, 13(11), 1810-1818.
  • Gore, M., Atkinson, R., Thomas, H., Cure, H., Rischin, D., Beale, P., Bougnoux, P., Dirix, L., Smit, W. (2002). Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. European Journal of Cancer, 38(supplement 8), s7-s12.
  • Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 11, 421-426.
  • Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.

2013

  • Finnigan, R., Hruby, G., Wratten, C., Keller, J., Tripcony, L., Dickie, G., Rischin, D., Poulsen, M. (2013). The Impact of Preradiation Residual Disease Volume on Time to Locoregional Failure in Cutaneous Merkel Cell Carcinoma-A TROG Substudy. International Journal of Radiation Oncology, Biology, Physics, 86(1), 91-95. [More Information]

2012

  • Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 8(3), 248-254. [More Information]

2011

  • Collins, I., Roberts-Thomson, R., Faulkner, D., Rischin, D., Friedlander, M., Mileshkin, L. (2011). Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls. International Journal Of Gynecological Cancer, 21(7), 1213-1218. [More Information]
  • Anglesio, M., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P., House, C., deFazio, A., et al (2011). IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 17(8), 2538-2548. [More Information]

2010

  • Reck, M., van Zandwijk, N., Gridelli, C., Baliko, Z., Rischin, D., Allan, S., Krzakowski, M., Heigener, D. (2010). Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. Journal of Thoracic Oncology, 5(10), 1616-1622. [More Information]

2007

  • Tinker, A., Gebski, V., Fitzharris, B., Buck, M., Stuart-Harris, R., Beale, P., Goldrick, A., Rischin, D. (2007). Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01. Gynecologic Oncology, 104(3), 647-653. [More Information]

2005

  • Rischin, D., Peters, L., Fisher, R., Macann, A., Denham, J., Poulsen, M., Jackson, M., Kenny, L., Penniment, M., Corry, J., et al (2005). Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). Journal of Clinical Oncology, 23(1), 79-87. [More Information]

2004

  • Rischin, D., Phillips, K., Friedlander, M., Harnett, P., Quinn, M., Richardson, G., Martin, A. (2004). A Phase II Trial Of Capecitabine In Heavily Pre-Treated Platinum-Resistant Ovarian Cancer. Gynecologic Oncology, 93(2), 417-421.

2003

  • Millward, M., Boyer, M., Lehnert, M., Clarke, S., Rischin, D., Goh, B., Wong, J., McNeil, E., Bishop, J. (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Annals of Oncology, 14(3), 449-454.

2002

  • Gore, M., Atkinson, R., Thomas, H., Cure, H., Rischin, D., Beale, P., Bougnoux, P., Dirix, L., Smit, W. (2002). A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. European Journal of Cancer, 38(18), 2416-2420.
  • Rischin, D., Ackland, S., Smith, J., Garg, M., Clarke, S., Millward, M., Toner, G., Zalcberg, J. (2002). Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies. Annals of Oncology, 13(11), 1810-1818.
  • Gore, M., Atkinson, R., Thomas, H., Cure, H., Rischin, D., Beale, P., Bougnoux, P., Dirix, L., Smit, W. (2002). Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. European Journal of Cancer, 38(supplement 8), s7-s12.

2000

  • Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 11, 421-426.
  • Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.

To update your profile click here. For support on your academic profile contact .